INSIGHTS ON DRUG DEVELOPMENT
-
Efficacy Evaluation Of AAV-Delivered Liver-Specific Promoters
Dr. Rui Sun, a Research Scientist at Bayer AG, discusses his work using Liver-Chips to assess the transduction efficiency and selectivity of liver-specific AAV promoters.
-
Assessing Developability And Designing Advanceable Formulations From The Start
Discover how early developability assessments and a quality-by-design approach can streamline formulation, reduce risk, and accelerate your path to successful, cost-effective drug development.
-
Democratizing Organ-On-A-Chip Technology
Learn about drug development challenges, the evolution of in vitro cell culture towards greater human relevance, a complete solution for creating human-relevant and translatable models, and more.
-
Advancing 3D Cell Culture Models For Clinical Relevance
Concerns about in vitro relevance and animal study limits have advanced cell culture tech. Explore how Organ-Chips offer a refined approach to studying human physiology.
-
ddPCR Workflows For Gene Expression Analysis3/5/2026
RT-ddPCR offers a powerful, flexible approach to precise RNA quantification. Learn how one-step and two-step workflows improve sensitivity and efficiency in your gene expression studies.
-
Characterizing Binding Interactions By ITC4/24/2025
Isothermal Titration Calorimetry is a powerful technique for analyzing biochemical binding events, which is crucial for understanding molecular interactions and enzyme kinetics in biomedical research.
-
In Vivo Testing Of Nasal Dosage Forms5/7/2025
Innovative nasal drug delivery strategies can unlock faster, patient-friendly therapeutic solutions by combining smart formulation, advanced testing platforms, and rigorous preclinical evaluation.
-
Breaking The Chains Of Conventional Drug Research Models8/7/2024
Gain insight into the limitations of conventional research models, how Organ-Chips are helping researchers bridge the translation gap and overcome pervasive barriers in drug development, and more.
-
Automating High-Throughput Screens Using Patient-Derived Organoids3/17/2025
Many oncology drugs fail in later development stages due to inadequate predictive models. Explore how 3D cell models, like patient-derived organoids, offer a promising solution in the drug development process.
DRUG DEVELOPMENT SOLUTIONS
-
Nanoform’s GMP facility utilizes its award-winning Controlled Expansion of Supercritical Solutions (CESS®) technology for the manufacture of API nanoparticles to GMP standards.
-
Overcome shared lab challenges with the Avanti JXN-30 high-speed centrifuge
- 4.0 L Max Capacity
- 30,000 RPM
- 110,510 x g
-
MabSelect™ VL resin — protein L resin for affinity capture of antibody Fabs, bispecifics, and other variants containing a kappa light chain.
-
AST’s line of table-top machines, GENiSYS® Lab, are ideal systems for drug product development and cGMP production applications. Each system is designed to automate the critical aseptic operations for vial, syringe and cartridge processing to reduce contamination risk and product variability. These table-top systems are engineered to have complete compatibility with cleanroom environments, including Laminar Air Flow Hoods, Bio-Safety Cabinets and aseptic isolators.
-
Observe how comprehensive R&D support advances therapeutic oligonucleotides from discovery through commercialization with tailored formulation development services across multiple modalities and delivery platforms.